Pharmacologypegfilgrastim stimulates the production, maturation, and activation of neutrophils and activates neutrophils to increase both their migration and cytotoxicity. pegfilgrastim has a prolonged duration of effect relative to filgrastim and a reduced renal clearance.indicationshematopoietic radiation injury syndrome (acute- neulasta only): to increase survival in patients acutely exposed to myelosuppressive doses of radiation.prevention of chemotherapy-induced neutropenia (fulphila [pegfilgrastim-jmdb- biosimilar] and neulasta): to decrease the incidence of infection (as manifested by febrile neutropenia), in patients with nonmyeloid malignancies receiving myelosuppressive cancer chemotherapy associated with a clinically significant incidence of febrile neutropenia.limitation of use: pegfilgrastim products are not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplant.